BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amakem NV to Present Top-Line Clinical Results for its Lead Candidate, AMA0076, at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Meeting 2013


11/7/2013 6:30:47 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Amakem to Present Top-Line Clinical Results for its Lead Candidate, AMA0076, at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Meeting 2013

DIEPENBEEK, Belgium, November 7, 2013 /PRNewswire/ -- Amakem Therapeutics, a clinical stage ophthalmology company, today announces that Dr. Jack Elands, CEO, will present at the Ophthalmology Innovation Summit (OIS) at the 2013 Annual Meeting of the American Academy of Ophthalmology.

Dr. Elands will present top-line clinical data on Amakem's lead drug candidate, the locally-acting Rho kinase (ROCK) inhibitor AMA0076 for the treatment of glaucoma. The presentation is scheduled to take place at the Sheraton New Orleans Hotel, New Orleans at 9.58am on Thursday November, 14.

About Amakem

Amakem is an ophthalmology company developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique Localized Drug Action platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.

Amakem's lead candidate, AMA0076, is for glaucoma and entered clinical development late last year. The Company is also working to apply the Localized Drug Action approach to a range of other eye diseases.

Founded in 2010, Amakem has raised more than €21m in funding and is backed by leading life sciences investors including Forbion, Omnes Capital (previously Crédit Agricole), Vesalius BioCapital, LRM, PMV/Vinnof and Life Science Research Partners.

Amakem is based in Belgium and located in the life sciences incubator "BioVille" at the University of Hasselt. The Company has a long-standing collaboration with Professor Ingeborg Stalmans at the Ophthalmology Research Center of the University Leuven Hospital, where it sponsors a Chair in Ophthalmology Translational Research.

For more information, please contact

Amakem NV

Jack Elands, CEO

jack.elands@amakem.com

+32(0)474-828-580

Citigate Dewe Rogerson

Chris Gardner

chris.gardner@citigatedr.co.uk

+44(0)20-7638-9571

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   
Glaucoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES